- Director of Digital Medicine, Assistant Professor of Cardiovascular Disease and Molecular Medicine, Scripps Research and Translational Institute.
- Serves as Regional Director of the Bluhm Cardiovascular Institute’s Clinical Trials Unit.
- Physician Entrepreneur with prior start up experience.
- Attended Stanford University, Medical School and Internal Medicine training at the University of California San Francisco
- Cardiovascular Diseases Fellowship Training at Northwestern University.
- Awarded American Heart Association Innovation Award, has completed a Device Development Fellowship and the LEAD Certificate From the Stanford School of Business.
- He has executed on multiple clinical trials and is well versed with taking an idea from zero to one and scaling to commercialization.
- President of PF Pharmaceutical Development, LLC, providing consultant services to the Pharmaceutical, Device, and Biotechnology Industries and to Venture Capital firms.
- Expertise in drug development, regulatory strategy, and translational science.
- Formerly Senior Director, vice-president, and CMO in large and small pharmaceutical companies, including Merck Research Laboratories, Bayer Pharmaceuticals, Karos Pharmaceuticals.
- Led large clinical programs for new antihypertensive and antidiabetic drugs development; mentored strong clinical teams; worked closely with basic science and commercial teams; headed company safety boards.
- Developed multiple cardiovascular, metabolic, and other compounds and achieved regulatory approval worldwide of three new molecular entities.
- Maintains an academic career as Clinical Associate Professor of Medicine at Weill Cornell Medical College where he is also a consultant to the Clinical Translational Science Center, developing courses in translational science and, until recently, attending physician at the Yale-affiliated VA Medical Center.
- Board certified in Internal Medicine and Nephrology, member, fellow, and on the board of several professional societies and small start-up companies.
- Dr Jack Henkin received his BA in Chemistry from City University of New York and PhD in Biochemistry from Brandeis University, then carried out postdoctoral studies in Bio-organic Chemistry at Harvard University and was assistant professor of Biochemistry and Molecular Biology at the U. of Texas Medical Center, Houston.
- Dr Jack Henkin received his BA in Chemistry from City University of New York and PhD in Biochemistry from Brandeis University, then carried out postdoctoral studies in Bio-organic Chemistry at Harvard University and was assistant professor of Biochemistry and Molecular Biology at the U. of Texas Medical Center, Houston.
- Returning full-time to academics as Research Professor at Northwestern University Center for Developmental Therapeutics he discovered novel PEDF-derived peptides aimed at retina disease, One of his patented peptides has recently been shown to protect retinal neuron death induced by amyloid Aβ oligomers, with potential for treating Alzheimer’s Disease. He also invented a novel nanoparticle-based platform for general intraocular drug delivery small peptide conjugated to nanocarrier via PEG linkers.
- Dr. Henkin is inventor on 13 US patents, author, or co-author of 98 refereed publications, and 12 invited reviews or book chapters. His drug development efforts brought proUK, r-UK, K5 and two peptides to drug candidacy, two recombinant thrombolytic proteins from bench to clinical phase III; and a synthetic anti-cancer peptide to Phase II clinical trials.
